LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "cdkn2a" as a keyword



Revisiting CDKN2A dysregulation in Ewing sarcoma

Sign Up to like & get
recommendations! Published in 2025 at "Molecular Oncology"

DOI: 10.1002/1878-0261.70008

Abstract: Ewing sarcoma (EwS) is a rare and aggressive malignancy, which frequently affects children. One of the few recurrent genomic variants in EwS is genomic copy number deletion of CDKN2A; however, the clinical consequences of dysregulation… read more here.

Keywords: revisiting cdkn2a; cdkn2a dysregulation; dysregulation ewing; ewing sarcoma ... See more keywords

Silencing of MEG3 inhibited ox‐LDL‐induced inflammation and apoptosis in macrophages via modulation of the MEG3/miR‐204/CDKN2A regulatory axis

Sign Up to like & get
recommendations! Published in 2019 at "Cell Biology International"

DOI: 10.1002/cbin.11105

Abstract: Atherosclerosis (AS) is one of the most common chronic inflammatory diseases and a major cause of morbidity and mortality. However, the underlying molecular mechanisms of the progression of AS are still largely unknown. Increasing evidence… read more here.

Keywords: meg3; cells treated; cdkn2a; mir 204 ... See more keywords

Perinatal DNA Methylation at CDKN2A Is Associated With Offspring Bone Mass: Findings From the Southampton Women's Survey

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Bone and Mineral Research"

DOI: 10.1002/jbmr.3153

Abstract: Poor intrauterine and childhood growth has been linked with the risk of osteoporosis in later life, a relationship that may in part be mediated through altered epigenetic regulation of genes. We previously identified a region… read more here.

Keywords: methylation; cdkn2a; bone; bone mass ... See more keywords

Hhex Regulates Hematopoietic Stem Cell Self‐Renewal and Stress Hematopoiesis via Repression of Cdkn2a

Sign Up to like & get
recommendations! Published in 2017 at "STEM CELLS"

DOI: 10.1002/stem.2648

Abstract: The hematopoietically expressed homeobox transcription factor (Hhex) is important for the maturation of definitive hematopoietic progenitors and B‐cells during development. We have recently shown that in adult hematopoiesis, Hhex is dispensable for maintenance of hematopoietic… read more here.

Keywords: hematopoiesis; cdkn2a; self renewal; hematopoietic stem ... See more keywords

CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort

Sign Up to like & get
recommendations! Published in 2020 at "Acta Neuropathologica"

DOI: 10.1007/s00401-020-02169-z

Abstract: Pediatric supratentorial ependymomas with RELA fusions (RELA-EP) have been identified as a unique novel tumor entity [9, 10]. Fusions between C11orf95 and RELA pathologically activate the NFκB signaling pathway indicated by nuclear accumulation of p65-RelA.… read more here.

Keywords: rela; p16 protein; cdkn2a deletion; cdkn2a ... See more keywords

CDKN2A/B status versus morphology in diagnosing WHO grade 4 IDH-mutated astrocytomas: what is the clinical relevance?

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Neuro-Oncology"

DOI: 10.1007/s11060-025-05078-x

Abstract: In the 2021 WHO classification system for central nervous system tumors, the diffuse glioma subgroup IDH-mutated (IDHm) astrocytomas WHO grade 4 was introduced. The diagnosis can be based upon molecular or histopathological morphological criteria. Here… read more here.

Keywords: idh mutated; grade; idhm astrocytoma; astrocytoma grade ... See more keywords

Methyltransferase Inhibition Enables Tgfβ Driven Induction of CDKN2A and B in Cancer Cells

Sign Up to like & get
recommendations! Published in 2023 at "Molecular and Cellular Biology"

DOI: 10.1080/10985549.2023.2186074

Abstract: Abstract CDKN2A/B deletion or silencing is common across human cancer, reinforcing the general importance of bypassing its tumor suppression in cancer formation or progression. In rhabdomyosarcoma (RMS) and neuroblastoma, two common childhood cancers, the three… read more here.

Keywords: cdkn2a; methyltransferase inhibition; tgf; cancer ... See more keywords

EPEN-14. MOLECULAR MARKERS AND PREDICTORS OF OUTCOME FOR PAEDIATRIC INTRACRANIAL EPENDYMOMA IN THE PROSPECTIVE, MULTICENTRE E-HIT2000 TRIAL AND SUBSEQUENT HIT-REGISTRIES: A POOLED ANALYSIS OF 244 PATIENTS

Sign Up to like & get
recommendations! Published in 2024 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noae064.216

Abstract: Abstract BACKGROUND Throughout the past decade, molecular tools have revolutionised ependymoma classification, yet their application has been limited in clinical trial cohorts. METHODS We present the molecular analysis of paediatric ependymoma patients from the E-HIT2000… read more here.

Keywords: analysis; trial; zfta; epn zfta ... See more keywords

JS05.6.A THE PROGNOSTIC IMPACT OF CDKN2A/B HETEROZYGOUS DELETIONS IN MENINGIOMA- INSIGHTS OF A MULTICENTER ANALYSIS

Sign Up to like & get
recommendations! Published in 2024 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noae144.031

Abstract: Meningiomas are one of the most common primary brain tumors. Homozygous deletions of CDKN2A/B have reliably been shown to confer an increased risk of progression. However, the role of heterozygous CDKN2A/B deletions remains less clear.… read more here.

Keywords: cdkn2a heterozygous; cdkn2a deletions; heterozygous cdkn2a; multicenter ... See more keywords

PATH-52. Understanding the prevalence of MTAP and CDKN2A/B deletion in gliomas by next generation sequencing

Sign Up to like & get
recommendations! Published in 2025 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noaf201.1004

Abstract: CDKN2A/B (cyclin-dependent kinase inhibitor 2A/B) gene alterations are integral to the diagnosis and prognostication of IDH-mutant gliomas. CDKN2A/B status is commonly assessed by next generation sequencing (NGS) or inferred from loss of the surrogate marker… read more here.

Keywords: deletion; next generation; cdkn2a deletion; mtap deletion ... See more keywords

PATH-64. Utility of p16 and MTAP Immunohistochemistry as a Surrogate for CDKN2A/B Homozygous Deletion and Prognostic Indicator in Meningiomas

Sign Up to like & get
recommendations! Published in 2025 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noaf201.1016

Abstract: The 2021 WHO Classification of CNS Tumors (5th edition) introduced molecular diagnostics into meningioma grading, designating CDKN2A/B homozygous deletion (homo-del) as a criterion for grade 3. Immunohistochemistry (IHC) for p16 (encoded by CDKN2A) and MTAP… read more here.

Keywords: cdkn2a; deletion; homozygous deletion; p16 mtap ... See more keywords